Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CET
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
11/21 JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA to Expand Indication..
11/21 JOHNSON & JOHNSON : California Judge Tosses Out $417 Million Verdict in Talc-Ova..
11/21 JOHNSON & JOHNSON : A Win for Johnson & Johnson in Baby Powder-Mesothelioma Case
11/20 JOHNSON & JOHNSON : to Participate in the Citi 2017 Global Healthcare Conference
11/20 JOHNSON & JOHNSON : New Real-World Analysis Shows INVOKANA® (canagliflozin) and ..
11/18 JOHNSON & JOHNSON : Analysis Shows INVOKANA Reduced Risk of Death, Cardiovascula..
11/17 JOHNSON & JOHNSON : New Real-World Analysis Shows INVOKANA® (canagliflozin) and ..
11/17 JOHNSON & JOHNSON : OneTouch® Launches #SmallVictories to Honor People Living wi..
11/16 JOHNSON & JOHNSON : A Win for Johnson & Johnson in Baby Powder-Mesothelioma Case
11/16 JOHNSON & JOHNSON : Federal Jury Returns $247 Million Verdict in Defective Hip I..
More news
News from SeekingAlpha
11/21 DGI, AI, And The 'Gig Economy' - A Millennial Perspective
11/21 MICROSOFT : Best Dow-Jones Wealth-Builder Stock Now
11/21 JOHNSON & JOHNSON : Dividend King With Good Total Return And Dividend Growth
11/21 Johnson & Johnson files marketing application in Europe for expanded use for ..
11/21 THE BAK PORTFOLIO :  Making Money On Cannabis And Tech
Financials ($)
Sales 2017 76 324 M
EBIT 2017 23 523 M
Net income 2017 16 391 M
Debt 2017 17 115 M
Yield 2017 2,42%
P/E ratio 2017 23,19
P/E ratio 2018 19,08
EV / Sales 2017 5,09x
EV / Sales 2018 4,70x
Capitalization 372 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 145 $
Spread / Average Target 4,7%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON19.78%371 653
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550
AMGEN16.27%122 526